For the Inventor, By the Inventor

Enter assignee name

New Haven, CT, United States of America

Achillion Pharmaceuticals, Inc.

USPTO Granted Patents = 104

% Expired Patents = 38.5

CIPO Patents = 1

EPO Patents = 29

Trademarks = 4

Forward Citations = 1,065

Loading Chart...

Loading Chart...

46 inventors (with patents filed for the assignee):

Avinash S Phadke (89 out of 89 patents)

Jason Allan Wiles (73 out of 82 patents)

Milind Deshpande (73 out of 77 patents)

4. Dawei Chen (70 out of 70 patents)

5. Xiangzhu Wang (69 out of 70 patents)

6. Akihiro Hashimoto (68 out of 68 patents)

7. Venkat Rao Gadhachanda (66 out of 66 patents)

8. Qiuping Wang (62 out of 62 patents)

9. Godwin Pais (61 out of 61 patents)

10. Atul Agarwal (56 out of 61 patents)

11. William J Greenlee (14 out of 157 patents)

12. Kyle J Eastman (10 out of 20 patents)

13. Suoming Zhang (10 out of 14 patents)

14. Cuixian Liu (9 out of 56 patents)

15. Joel Charles Barrish (8 out of 9 patents)

Core Competencies:

Pharmaceutical Compounds

Complement Mediated Disorders

Immune Disorders

Viral Replication

Macrocyclic Compounds

Aryl Compounds

Heteroaryl Compounds

HCV Infections

Therapeutic Regimens

Inflammatory Disorders

Morphic Forms

Peptides

104 patents: Sort by Forward Citations

1. 12479856 - Pharmaceutical compounds for the treatment of complement mediated disorders (2025-11-25),

2. 12338230 - Aryl, heteroaryl, and heterocyclic compounds for treatment of immune and inflammatory disorders (2025-06-24),

3. 12297205 - Macrocyclic compounds for treatment of medical disorders (2025-05-13),

4. 12239645 - Targeted dosing for the treatment of complement mediated disorders (2025-03-04),

5. 12162860 - Aryl, heteroaryl, and heterocyclic pharmaceutical compounds for treatment of medical disorders (2024-12-10),

6. 12139497 - Aryl, heteroaryl, and heterocyclic compounds for treatment of medical disorders (2024-11-12),

7. 12076319 - Therapeutic regimens for treatment of paroxysmal nocturnal hemoglobinuria (2024-09-03),

8. 12065459 - Aryl, heteroaryl, and heterocyclic compounds for treatment of complement mediated disorders (2024-08-20),

9. 12006307 - Pharmaceutical compounds for treatment of medical disorders (2024-06-11),

10. 11926617 - Aryl, heteroaryl, and heterocyclic compounds for treatment of immune and inflammatory disorders (2024-03-12),

11. 11814391 - Macrocyclic compounds for the treatment of medical disorders (2023-11-14),

12. 11814363 - Morphic forms of danicopan (2023-11-14),

13. 11807627 - Morphic forms of complement factor D inhibitors (2023-11-07),

14. 11718626 - Macrocyclic compounds for treatment of medical disorders (2023-08-08),

15. 11708351 - Aryl, heteroaryl, and heterocyclic pharmaceutical compounds for treatment of medical disorders (2023-07-25),

Company Overview

Achillion Pharmaceuticals, Inc., based in New Haven, CT, specializes in the development of innovative pharmaceutical compounds targeting complement-mediated disorders and immune disorders. The company focuses on advancing therapies for viral replication, particularly in the context of HCV infections. Achillion's research encompasses a range of chemical entities, including macrocyclic, aryl, and heteroaryl compounds, aimed at addressing significant unmet medical needs in the field of infectious diseases and immune-related conditions.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 6 2026

104 Patents

#4 in New Haven, CT

#105 in Connecticut

#3,657 in US

#7,516 in the World

New Haven, CT, United States of America

Achillion Pharmaceuticals, Inc.

Forward Citations = 1,065

46 inventors:

Avinash S Phadke (89 out of 89 patents)

Jason Allan Wiles (73 out of 82 patents)

Milind Deshpande (73 out of 77 patents)

4. Dawei Chen (70 out of 70 patents)

5. Xiangzhu Wang (69 out of 70 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Achillion Pharmaceuticals, Inc.. Retrieved from https://idiyas.com/company/achillion-pharmaceuticals

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…